Comparative efficacy of tarlatamab and second-line therapies in extensive-stage small cell lung cancer: A network meta-analysis
A new targeted immunotherapy for small-cell lung cancer significantly extends survival compared to all current standard second-line treatments.
A Bayesian network meta-analysis integrating Phase 3 DeLLphi-304 trial data confirms tarlatamab (DLL3-targeting BiTE) provides significantly better overall survival than all available second-line treatments for extensive-stage SCLC, including platinum rechallenge in platinum-sensitive patients. These findings support tarlatamab as a potential new standard of care in 2L ES-SCLC across all patient subgroups.
What the study was
- Study design
- Bayesian network meta-analysis
- Population
- Previously treated extensive-stage SCLC patients (2L setting), overall and platinum-sensitive subgroup
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Lung Cancer
Why it surfaced
First comprehensive NMA positioning tarlatamab against the full 2L ES-SCLC treatment landscape including platinum rechallenge; confirms superiority across all comparators. SCLC has very high unmet need with historically poor 2L outcomes. Important COI note: all primary authors employed by Amgen (tarlatamab manufacturer) or Analysis Group (paid consultant).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.